NVO241108C118000
- 0.99
- -0.71-41.76%
Novo-Nordisk A/S Newsroom
Top Gap Ups and Downs on Monday: CHWY, FSLR, NVO and More
US stocks closed: Trump, Harris concept stocks rose together, Chinese concept stocks remained stable and rose.
1. The market is filled with a wait-and-see attitude, with all three major indexes collectively falling. 2. Trump's media technology group rebounded after hitting bottom. 3. Photovoltaic and clean energy concept stocks strengthened collectively. 4. Reports claim that Nvidia will distribute Super Micro Computer orders to other suppliers.
Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ
How Does Viking's Weight Loss Med Compare to Ones From Novo, Eli Lilly?
Viking Stock Drops 13% After Jumping 9% on Obesity Drug Data
New Study Reveals Another Benefit in Using Novo Nordisk's Wegovy in Obesity
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Nvidia rises to the top again! Surpassing Apple to become the global market cap leader.
The global market cap leader changes hands again.
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
What's Going On With Hims & Hers Health Stock Monday?
Novo Holdings Planned $16.5B Planned Acquisitions of Catalent Gets EU Inquiry
Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview
Novo Nordisk, Ascendis Partner to Advance Once-monthly Obesity Drug Candidate
New weight loss drug CagriSema planned to be launched by novo-nordisk a/s is expected to alleviate the problem of rebound after discontinuation, with a minimum weight loss of 25%!
CagriSema combines the two ingredients of semaglutide and pancreatic amylase, is expected to achieve the best efficacy in history with a 25% weight loss, compared to the previous generation of weight loss drug Wegovy, it will not bring additional side effects, and is expected to alleviate gastrointestinal side effects such as nausea and vomiting.
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
Ascendis Pharma, Novo Nordisk Partner For Development, Commercialization Of TransCon Technology-Based Products In Metabolic, Cardiovascular Diseases; Ascendis To Be Eligible To Receive Payments Of Up To $285M For Lead Program
This Pharma Stock Is Soaring 21%. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo. -- Barrons.com
Stock market anomaly | viking therapeutics (VKTX.US) surged 24% pre-market, significant early research effectiveness of oral weight loss drugs.
Biotechnology company Viking Therapeutics' stock price rose 23.90% in pre-market trading as of Monday.
Novo Nordisk's Wegovy Trial in Liver Disease Is a Small Positive -- Market Talk
Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ